Who Paid My Doc
Rebecca Stone
Obstetrics & Gynecology Baltimore, MD Medical Doctor
NPI 1033324793 CMS profile 1246610
601 N Caroline St, Baltimore, MD 21287
General payments
$87,986
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$55,041
Through program year 2025, Rebecca Stone of Baltimore, MD is reported in the CMS Open Payments database as having received $87,986 across 33 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $55,041 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $340 | 11 | |
| 2024 | General | $1,047 | 4 | |
| 2023 | General | $8,372 | 5 | |
| 2022 | General | $35,278 | 3 | |
| 2021 | General | $30,358 | 4 | |
| 2020 | General | $1,650 | 2 | |
| 2019 | General | $10,941 | 4 |
Beside peers
- Rebecca Stone
- Obstetrics & Gynecology median
- Middle half of Obstetrics & Gynecology
- National median
In program year 2025, general payments to Rebecca Stone were reported at $340. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.
Show as a table
| Year | Rebecca Stone | Obstetrics & Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $10,941 | $172 | $62–$391 | $163 |
| 2020 | $1,650 | $94 | $36–$222 | $114 |
| 2021 | $30,358 | $136 | $42–$369 | $132 |
| 2022 | $35,278 | $160 | $50–$433 | $149 |
| 2023 | $8,372 | $169 | $56–$423 | $160 |
| 2024 | $1,047 | $152 | $50–$371 | $164 |
| 2025 | $340 | $158 | $51–$401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
172
Drug cost
$19,426
Branded share of claims
12.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 22 | $11,550 | |
| Estradiol | Generic | 24 | $6,019 | |
| Letrozole | Generic | 35 | $592 | |
| Tamoxifen Citrate | Generic | 22 | $471 | |
| Norethindrone Acetate | Generic | 14 | $458 | |
| Megestrol Acetate | Generic | 13 | $184 | |
| Ondansetron Hcl | Generic | 17 | $74 | |
| Pantoprazole Sodium | Generic | 14 | $55 | |
| Prednisone | Generic | 11 | $23 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 860 Part D prescribers listed as Gynecological Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 52 billing codesPaid by Medicare
$63,378
Medicare patients
218
Services billed
484
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Cancer | 53% | |
| Arthritis | 45% | |
| Depression | 29% | |
| Diabetes | 25% | |
| Osteoporosis | 25% | |
| Chronic kidney disease | 22% | |
| Ischemic heart disease | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
33 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obstetrics & Gynecology in Maryland
Otis Stitt
Obstetrics & Gynecology · Silver Spring, MD
Danielle Shiller
Obstetrics & Gynecology · Baltimore, MD
Matthew Reeves
Obstetrics & Gynecology · Chevy Chase, MD
Karen Wang
Obstetrics & Gynecology · Baltimore, MD
Abigail Gregory
Obstetrics & Gynecology · Oakland, MD
Christina Enzmann
Obstetrics & Gynecology · Baltimore, MD
Related records
Obstetrics & Gynecology in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Obstetrics & Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.